公司資料
Tenaya Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TNYA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.70 USD (+0.98%)
收盤價
最後更新: 2026年8月21日
171M USD
市值
股價為何變動
As of Aug 21, 2026, TNYA closed up 0.98% at $0.6973. No new same-company headline was identified in the current news window.
公司概覽
Genetically Informed Cardiac Therapies
Tenaya Therapeutics develops gene therapies and small molecules that address underlying drivers of inherited and prevalent heart disease.
TN-201
TN-201 is an AAV gene therapy for hypertrophic cardiomyopathy caused by MYBPC3 mutations. The Phase 1b/2 MyPEAK-1 study is evaluating two dose cohorts in adults.
TN-401
TN-401 is an AAV gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. RIDGE-1 is assessing safety, cardiac biomarkers and early measures of disease activity.
TN-301
TN-301 is a selective HDAC6 inhibitor with potential applications in heart failure with preserved ejection fraction, Duchenne muscular dystrophy and other cardiac or muscular disorders.
Discovery Collaborations
Tenaya combines internal target discovery with external collaborations, including work with Alnylam to identify and validate genetic targets for cardiovascular disease.
未來催化劑
- One-year Cohort 1 and initial Cohort 2 RIDGE-1 data for TN-401 at ASGCT 2026.
- Updated Cohort 1 and Cohort 2 MyPEAK-1 data for TN-201 in the second quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。